loperamide has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elia, SG | 1 |
| Al-Karmalawy, AA | 1 |
| Nasr, MY | 1 |
| Elshal, MF | 1 |
1 other study available for loperamide and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female | 2022 |